ZA201403861B - Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses - Google Patents

Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Info

Publication number
ZA201403861B
ZA201403861B ZA2014/03861A ZA201403861A ZA201403861B ZA 201403861 B ZA201403861 B ZA 201403861B ZA 2014/03861 A ZA2014/03861 A ZA 2014/03861A ZA 201403861 A ZA201403861 A ZA 201403861A ZA 201403861 B ZA201403861 B ZA 201403861B
Authority
ZA
South Africa
Prior art keywords
sialoadhesin
inhibitors
treatment
diseases caused
enveloped viruses
Prior art date
Application number
ZA2014/03861A
Other languages
English (en)
Inventor
Izquierdo Useros Nuria
Martínez Picado Javier
Lorizate Maier
Kraüsslich Hans-Georg
Original Assignee
Ruprecht-Karls-Universitaet Heidelberg
Institució Catalana De Recerca I Estudis Avançats
Fundació Privada Inst De Recerca De La Sida - Caixa
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruprecht-Karls-Universitaet Heidelberg, Institució Catalana De Recerca I Estudis Avançats, Fundació Privada Inst De Recerca De La Sida - Caixa, Esteve Labor Dr filed Critical Ruprecht-Karls-Universitaet Heidelberg
Publication of ZA201403861B publication Critical patent/ZA201403861B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA2014/03861A 2011-12-22 2014-05-27 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses ZA201403861B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579242P 2011-12-22 2011-12-22
EP11382392.6A EP2606897A1 (en) 2011-12-22 2011-12-22 Methods and compositions for the treatment of diseases caused by enveloped viruses
PCT/EP2012/075831 WO2013092509A1 (en) 2011-12-22 2012-12-17 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Publications (1)

Publication Number Publication Date
ZA201403861B true ZA201403861B (en) 2015-09-30

Family

ID=45445920

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03861A ZA201403861B (en) 2011-12-22 2014-05-27 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Country Status (14)

Country Link
US (1) US9789130B2 (enExample)
EP (2) EP2606897A1 (enExample)
JP (1) JP6143781B2 (enExample)
KR (1) KR20140130664A (enExample)
CN (1) CN104168903B (enExample)
AU (1) AU2012357968B2 (enExample)
BR (1) BR112014015112A8 (enExample)
CA (1) CA2858499A1 (enExample)
HK (1) HK1202820A1 (enExample)
IL (1) IL233207A0 (enExample)
MX (1) MX2014007605A (enExample)
RU (1) RU2014130022A (enExample)
WO (1) WO2013092509A1 (enExample)
ZA (1) ZA201403861B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004695B2 (en) 2014-04-16 2018-06-26 Trustees Of Boston University GM3 functionalized nanoparticles
CN104587491A (zh) * 2014-12-30 2015-05-06 天津大学 SAMHD1-pLNCX2制备抗肿瘤药物的用途
AU2017261840A1 (en) * 2016-05-06 2018-11-22 WRS Nutraceuticals Pty Ltd Agent delivery system
CN109906381B (zh) * 2016-08-31 2023-03-31 新加坡科技研究局 鉴别、靶向以及分离人树突细胞(dc)前体“前dc”的方法及其用途
CN108165559B (zh) * 2017-11-29 2021-06-18 昆明理工大学 一种c2h2型转录因子基因及其应用
KR20230099676A (ko) * 2021-12-27 2023-07-04 주식회사 진켐 시알릴락토스를 이용한 혈뇌장벽 투과용 약물 전달체
US20250302865A1 (en) * 2022-03-16 2025-10-02 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
KR20240102304A (ko) * 2022-12-26 2024-07-03 주식회사 진켐 신규한 젬시타빈 결합체 및 이의 용도
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3888975A (en) 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
FR2433949A1 (fr) 1978-08-25 1980-03-21 Commissariat Energie Atomique Substrat hydrophobe apte a liberer une substance chimique
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4360013A (en) 1980-04-21 1982-11-23 Minnesota Mining And Manufacturing Company Polymeric acid contraceptive devices
IT1131833B (it) 1980-06-20 1986-06-25 Crinos Industria Farmaco Eccipienti per sostanze spermicide
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
US4415585A (en) 1982-03-11 1983-11-15 University Of Illinois Foundation Contraceptive method
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5248700A (en) 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4499154A (en) 1982-09-03 1985-02-12 Howard L. Podell Dipped rubber article
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE4015543A1 (de) 1990-05-15 1991-11-21 Bayer Ag Spermicides beschichtungsmittel
DE69119312T2 (de) 1990-07-18 1997-01-16 Abbott Lab Analyt-Austauschreagenz zur Verwendung in spezifischen Bindungstests, -vorrichtungen und -sätzen
US5143731A (en) 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
FR2666587B1 (fr) 1990-09-10 1993-06-25 Dow Corning Sa Compositions de lubrifiant et leur utilisation.
GB9021061D0 (en) 1990-09-27 1990-11-07 Unilever Plc Encapsulating method and products containing encapsulated material
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
SE9700383D0 (sv) 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
CA2340118C (en) 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
EP1168924A4 (en) 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
MXPA03005373A (es) 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP5231231B2 (ja) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
JP5641598B2 (ja) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 シアリルラクトース素材の分離方法
JP5788653B2 (ja) * 2010-09-10 2015-10-07 靖人 江原 糖鎖修飾ヌクレオチド及びその使用

Also Published As

Publication number Publication date
AU2012357968B2 (en) 2017-10-05
MX2014007605A (es) 2015-07-06
US20140370052A1 (en) 2014-12-18
RU2014130022A (ru) 2016-02-10
CA2858499A1 (en) 2013-06-27
EP2606897A1 (en) 2013-06-26
US9789130B2 (en) 2017-10-17
EP2793904A1 (en) 2014-10-29
IL233207A0 (en) 2014-07-31
JP6143781B2 (ja) 2017-06-07
JP2015500854A (ja) 2015-01-08
CN104168903B (zh) 2017-05-31
HK1202820A1 (en) 2015-10-09
CN104168903A (zh) 2014-11-26
BR112014015112A2 (pt) 2017-06-13
WO2013092509A1 (en) 2013-06-27
NZ627650A (en) 2016-01-29
KR20140130664A (ko) 2014-11-11
BR112014015112A8 (pt) 2017-06-13
AU2012357968A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL262200A (en) Methods for treating Alport syndrome
IL233207A0 (en) Preparations containing an inhibitor of sialoadhesin and their use for the treatment of viral diseases
ZA201402424B (en) 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
ZA201403795B (en) Formulations for the treatment of diabetes
ZA201309557B (en) Methods of treatment for retinal diseases
EP2718255A4 (en) QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
ZA201308194B (en) Treatment of mastitis
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system
SG11201402899TA (en) Methods and compositions for treating viral diseases
GB201105302D0 (en) Treatment of acidosis
GB201217331D0 (en) Novel compound useful for the treatment of infectious diseases
IL232294B (en) Preparations for the treatment of diabetes
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease
GB201121228D0 (en) Novel compounds and improved treatments for glaucoma
ZA201308902B (en) Quinone compounds for treating ape1 mediated diseases
EP2747765A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES